Aspira enters lab services pact with Mayo Clinic for Ova1Plus and OvaWatch tests

Aspira Women's Health Inc.

Agreement effective Dec 16, 2025; Mayo will list Aspira’s Ova1Plus and OvaWatch in its test catalog.
Mayo obligated to set minimum list prices (redacted); will market tests to its clients.
Initial term (redacted years) with automatic renewal; either party may terminate without cause on (redacted) days notice.
Testing is non-exclusive and on an as-requested basis; many financial terms remain confidential.
Partnership leverages Mayo’s national distribution to expand reach of Aspira’s ovarian cancer tests.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Aspira Women's Health Inc. entered into Laboratory Services Agreement with Mayo Collaborative Services, Inc. d/b/a Mayo Clinic Laboratories valued at Not disclosed (effective 2025-12-16).

Action: entry
Agreement: supply
Counterparty: Mayo Collaborative Services, Inc. d/b/a Mayo Clinic Laboratories
Value: Not disclosed
Effective: 2025-12-16

Exact text from the filing

On December 23, 2025, Aspira Women’s Health Inc. (“Aspira”) disclosed that we had entered into a Laboratory Services Agreement (the “Agreement”) with Mayo Collaborative Services, Inc., d/b/a Mayo Clinic Laboratories (“Mayo”), effective as of December 16, 2025.

View on SEC.gov

299 material agreements filed in the last 30 days. Browse all material agreements →

Aspira Women's Health Inc. filing history →

Source: SEC EDGAR

accession 0000926617-26-000012

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.